The need for evidence-based treatment decisions in spinal muscular atrophy type 0
- PMID: 34546649
- PMCID: PMC8528450
- DOI: 10.1002/acn3.51459
The need for evidence-based treatment decisions in spinal muscular atrophy type 0
Conflict of interest statement
N.G. is an advisor and lecturer for Biogen, Novartis, Novartis Gene Therapies (AveXis) and Roche.
Comment in
-
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0.Ann Clin Transl Neurol. 2021 Oct;8(10):2093. doi: 10.1002/acn3.51458. Epub 2021 Sep 21. Ann Clin Transl Neurol. 2021. PMID: 34546660 Free PMC article. No abstract available.
Comment on
-
Nusinersen in type 0 spinal muscular atrophy: should we treat?Ann Clin Transl Neurol. 2020 Dec;7(12):2481-2483. doi: 10.1002/acn3.51126. Epub 2020 Nov 4. Ann Clin Transl Neurol. 2020. PMID: 33147378 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical